Importantly, a dose–response effect was observed, with higher doses resulting in a more rapid improvement of the disease phenotype, thus validating the disease severity model generated, and confirming a reduction of the myopathy features in a dose–response manner following Dnm2 reduction. This evidence concerns the gene DNM2 and myopathy.